Ubiquitin-immunoreactive degradation products of cytokeratin 8/18 correlate with aggressive breast cancer

Cancer Science

Volumn 94, Issue 10, 2003, Pages 864-870

  Iwaya, Keiichi ^a   Ogawa, Hitoshi ^a   Mukai, Yasuo ^a   Iwamatsu, Akihiro ^b   Mukai, Kiyoshi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b KIRIN BREWERY CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8; MONOCLONAL ANTIBODY; PROTEASOME; PROTEIN P53; UBIQUITIN;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER TISSUE; CELL STRUCTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; GEL ELECTROPHORESIS; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; SEQUENCE ANALYSIS;

ADULT; AGED; AMINO ACID SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; KERATINS; MASS SPECTROMETRY; MICROSCOPY, CONFOCAL; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; NEOPLASM METASTASIS; PEPTIDE FRAGMENTS; PRECIPITIN TESTS; UBIQUITIN;

EID: 0242525131     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01368.x     Document Type: Article

References (43)

1. Ozkaynak E, Finley D, Varshavsky A. The yeast ubiquitin gene: head-to-tail repeats encoding a polyubiquitin precursor protein. Nature 1984; 312: 663-6.
2. Hershko A, Ciechanover A, Varshavsky A. Basic Medical Research Award. The ubiquitin system. Nat Med 2000; 6: 1073-81.
3. Hershko A, Leshinsky E, Ganoth D, Heller H. ATP-dependent degradation of ubiquitin-protein conjugates. Proc Natl Acad Sci USA 1984; 81: 1619-23.
4. Bachmair A, Varshavsky A. The degradation signal in a short-lived protein. Cell 1989; 56: 1019-32.
5. Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioassays 2000; 22: 442-51.
6. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, Klausner RD, Pause A. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 1999; 96: 12436-41.
7. Ishibashi Y, Takada K, Joh K, Ohkawa K, Aoki T, Matsuda M. Ubiquitin immunoreactivity in human malignant tumours. Br J Cancer 1991; 63: 320-2.
8. Osada T, Sakamoto M, Nishibori H, Iwaya K, Matsuno Y, Muto T, Hirohashi S. Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver. J Hepatol 1997; 26: 1266-73.
9. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science 199 1; 252: 1708-11.
10. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
11. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
12. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, McMahon M, Oren M, McCormick F. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000; 103: 321-30.
13. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991; 82: 835-40.
14. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993; 72: 3641-7.
15. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995; 13: 821-30.
16. Iwaya K, Tsuda H, Fukutomi T, Tsugane S, Suzuki M, Hirohashi S. Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer. Jpn J Clin Oncol 1997; 27: 6-12.
17. Iwaya K, Tsuda H, Fujita S, Suzuki M, Hirohashi S. Natural state of mutant p53 protein and heat shock protein 70 in breast cancer tissues. Lab Invest 1995; 72: 707-14.
18. Band V, De Caprio JA, Delmolino L, Kulesa V, Sager R. Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. J Virol 1991; 65: 6671-6.
19. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9.
20. Sato Y, Mukai K, Watanabe S, Goto M, Shimosato Y. The AMeX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol 1986; 125: 431-5.
21. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
23. Kanayama H, Tanaka K, Aki M, Kagawa S, Miyaji H, Satoh M, Okada F, Sato S, Shimbara N, Ichihara A. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res 1991; 51: 6677-85.
24. Nishibori H, Matsuno Y, Iwaya K, Osada T, Kubomura N, Iwamatsu A, Kohno H, Sato S, Kitajima M, Hirohashi S. Human colorectal carcinomas specifically accumulate Mr 42,000 ubiquitin-conjugated cytokeratin 8 fragments. Cancer Res 1996; 56: 2752-7.
25. Iwamatsu A. S-Carboxymethylation of proteins transferred onto polyvinylidene difluoride membranes followed by in situ protease digestion and amino acid microsequencing. Electrophoresis 1992; 13: 142-7.
26. Aebersold RH, Leavitt J, Saavedra RA, Hood LE, Kent SB. Internal amino acid sequence analysis of proteins separated by one- or two-dimensional gel electrophoresis after in situ protease digestion on nitrocellulose. Proc Natl Acad Sci USA 1987; 84: 6970-4.
27. Henzel WJ, Billeci TM, Stults JT, Wong SC, Grimley C, Watanabe C. Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc Natl Acad Sci USA 1993; 90: 5011-5.
28. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998; 90: 1601-8.
29. Caulin C, Salvesen GS, Oshima RG. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 1997; 138: 1379-94.
30. Ku NO, Omary MB. Keratins turn over by ubiquitination in a phosphorylation modulated fashion. J Cell Biol 2000; 149: 547-52.
31. Chen PH, Ornelles DA, Shenk T. The adenovirus L3 23-kilodalton proteinase cleaves the amino-terminal head domain from cytokeratin 18 and disrupts the cytokeratin network of HeLa cells. J Virol 1993; 67: 3507-14.
32. Breitkreutz D, Boukamp P, Ryle CM, Stark HJ, Roop DR, Fusenig NE. Epidermal morphogenesis and keratin expression in c-Ha-ras-transfected tumorigenic clones of the human HaCaT cell line. Cancer Res 1991; 51: 4402-9.
33. Paine TM, Fontanini G, Basolo F, Geronimo I, Elliott JW, Russo J. Mutated c-Ha-ras oncogene alters cytokeratin expression in the human breast epithelial cell line MCF-10A. Am J Pathol 1992; 140: 1483-8.
34. Dairkee S, Heid HW. Cytokeratin profile of immunomagnetically separated epithelial subsets of the human mammary gland. In Vitro Cell Dev Biol Anim 1993; 29A: 427-32.
35. Dairkee SH, Puett L, Hackett AJ. Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue. J Natl Cancer Inst 1988; 80: 691-5.
36. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998; 433: 119-29.
37. Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, Weitzel H, Lengyel E. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 1996; 2: 1879-85.
38. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
39. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
40. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P. Expression of cytokeratin 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002; 161: 1991-6.
41. Bader BL, Magin TM, Freudenmann M, Stumpp S, Franke WW. Intermediate filaments formed de novo from tail-less cytokeratins in the cytoplasm and in the nucleus. J Cell Biol 1991; 115: 1293-307.
42. Franke WW, Schmid E, Wellsteed J, Grund C, Gigi O, Geiger B. Change of cytokeratin filament organization during the cell cycle: selective masking of an immunologic determinant in interphase PtK2 cells. J Cell Biol 1983; 97: 1255-60.
43. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H, Schutte B. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999; 187: 567-72.